Medical Oncology Research

The Medical Oncology Clinical Trials Unit was established in 1985 and is integrated within the Medical Oncology department. We value multidisciplinary and interdepartmental research. Our research portfolio includes:

Phase I, II and III interventional clinical trials
Observational studies
Studies inclusive of a broad range of cancer types
Studies on the assessment and management of cancer
Studies on the psychosocial and survivorship care of people with cancer
Studies to improve the health care delivery of people with cancer

We support industry and investigator-led studies. We collaborate with Cancer Cooperative Groups, universities, and pharmaceutical companies to identify and conduct important research studies that will improve the lives of people with cancer.

Our team are experienced, enthusiastic, and diligent in their research activities, and share knowledge from their diverse backgrounds in nursing, science, and ethics to improve the unit. We provide a constant point of contact for sponsored studies. Our role in each study is determined by individual trial requirements and may include assistance with ethics submissions, recruitment, participant visits and data management.

All staff participate in professional development activities, such as attendance at educational events and conferences, to consolidate and improve their research knowledge and skills.

Selected Grants

Amount awarded	Grant and project details
$1,362,000	NHMRC Clinical Trial and Cohort Studies, 2024-2027 P3BEP Trial - Accelerating firstlLine chemotherapy to improve cure rates for advanced germ cell tumours – An Australian-led, international randomised trial. Investigators: Grimison G, Stockler M, Martin A, Tran B, Frazier L, Huddart R, Walker R, Mazhar D, Feldman D, Zawa P.
$20,000	Sydney Local Health District, 2024-2025 The safety and tolerability of Annona muricata leaf extract in people living with cancer: Pilot Study. Investigators: Bui KT, Beale P.
$600,000	NHMRC, 2023-2026 Intraperitoneal bevacizumab for recurrent malignant ascites (REZOLV3R) Investigator: Stockler M
$494,132	NHMRC, 2023-2026 ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer Investigators: Mileshkin L, Lee YC, Friedlander M, Brand A, Ledermann J, Davis A, Beale P, Coward J, Viney R
$1,600,000	NHMRC, 2020-2025 Improving long term health for cancer survivors Investigator: Vardy J

Our Publications

2024

Tan SY, Dhillon HM, Mak C, Liang R, Kerin-Ayres K, Vuong K, Malalasekera A, Vardy JL. Utility of survivorship care plans: A mixed-method study exploring general practitioners' and cancer specialists' views. Asia Pac J Clin Oncol. 2024 Feb;20(1):128-137. doi: 10.1111/ajco.14038. Epub 2023 Dec 5.

Subramaniam S, Adams DH, Tognela A, Roncolato F, Yip PY, Lim SH, Roohullah A, Stockler MR, Kiely B. Patients' perception of the benefits of palliative systemic therapy for advanced cancer. Intern Med J. 2024 May;54(5):735-741. doi: 10.1111/imj.16325. Epub 2024 Jan 11.

Nahm SH, Subramaniam S, Stockler MR, Kiely BE. Timing of prognostic discussions in people with advanced cancer: a systematic review. Support Care Cancer. 2024 Jan 23;32(2):127. doi: 10.1007/s00520-023-08230-3.

Roncolato F, King MT, O'Connell RL, Lee YC, Joly F, Hilpert F, Lanceley A, Yoshida Y, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Kaminsky MC, Stockler MR, Friedlander M. Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. Gynecol Oncol. 2024 Jun;185:128-137. doi: 10.1016/j.ygyno.2024.02.025. Epub 2024 Feb 26.

Tan L, Brown C, Mersiades A, Lee CK, John T, Kao S, Newnham G, O'Byrne K, Parakh S, Bray V, Jasas K, Yip S, Wong SQ, Ftouni S, Guinto J, Chandrashekar S, Clarke S, Pavlakis N, Stockler MR, Dawson SJ, Solomon BJ. A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nat Commun. 2024 Feb 28;15(1):1823. doi: 10.1038/s41467-024-46008-1.

Mahon KL, Sutherland SI, Lin HM, Stockler MR, Gurney H, Mallesara G, Briscoe K, Marx G, Higano CS, de Bono JS, Chi KN, Clark G, Breit SN, Brown DA, Horvath LG. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. Prostate. 2024 Jun;84(8):747-755. doi: 10.1002/pros.24691. Epub 2024 Mar 27.

Naher SK, Mercieca-Bebber R, Siu D, Stockler MR, Kiely BE, Grimison P. Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials. Curr Med Res Opin. 2024 Aug;40(8):1357-1367. doi: 10.1080/03007995.2024.2376129. Epub 2024 Jul 13.

Soon YY, Marschner IC, Schou M, Sweeney CJ, Davis ID, Stockler MR, Martin AJ. Challenges of estimating treatment effects after a positive interim analysis. Eur J Cancer. 2024 Sep;209:114230. doi: 10.1016/j.ejca.2024.114230. Epub 2024 Jul 19.

Kim GY, Conduit C, O'Haire S, Chong CY, Baenziger O, Lewin J, Thomas B, Lawrentschuk N, Stockler MR, Olver I, Grimison P, Tran B. Association between low total serum testosterone and body mass index in Australian survivors of testicular cancer: a retrospective analysis. Basic Clin Androl. 2024 Sep 3;34(1):14. doi: 10.1186/s12610-024-00230-5.

Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30.

Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12.

Grimison P, Mersiades A, Kirby A, Tognela A, Olver I, Morton RL, Haber P, Walsh A, Lee Y, Abdi E, Della-Fiorentina S, Aghmesheh M, Fox P, Briscoe K, Sanmugarajah J, Marx G, Kichenadasse G, Wheeler H, Chan M, Shannon J, Gedye C, Begbie S, Simes RJ, Stockler MR. Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. J Clin Oncol. 2024 Dec;42(34):4040-4050. doi: 10.1200/JCO.23.01836. Epub 2024 Aug 16.

Sharifi N, Diaz R, Lin HM, Roberts E, Horvath LG, Martin A, Stockler MR, Yip S, Subhash VV, Portman N, Davis ID, Sweeney CJ. Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. J Clin Invest. 2024 Sep 17;134(18):e183583. doi: 10.1172/JCI183583.

Soon YY, Marschner IC, Schou M, Hofman MS, Emmett L, Davis ID, Stockler MR, Martin AJ. Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2024 Sep 3;7(9):e2433863. doi: 10.1001/jamanetworkopen.2024.33863.

Meade A, Frangou E, Choodari-Oskooei B, Larkin J, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Gedye C, Harrison DJ, Kaplan R, Mulhere S, Nathan P, Patel G, Patel J, Plant H, Ritchie A, Rush H, Shakeshaft C, Stockler MR, Suarez C, Thompson J, Thorogood N, Venugopal B, Parmar MKB. Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report. Contemp Clin Trials Commun. 2024 Oct 18;42:101381. doi: 10.1016/j.conctc.2024.101381.

Mellor R, Ardolino L, Scheinberg T, Fitzpatrick M, Lin HM, Bonnitcha P, Sullivan D, Meikle PJ, Stockler MR, Moujaber T, Joshua A, Horvath L. Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy. Ther Adv Med Oncol. 2024 Dec 16;16:17588359241307814. doi: 10.1177/17588359241307814.

Lee CK, Liao BC, Subramaniam S, Chiu CH, Mersiades AJ, Ho CC, Brown C, Lai CL, Hughes BGM, Yang TY, O'Byrne K, Luo YH, Yip S, Ho CL, Bray V, Su WC, Moore M, Feng WL, Bai YY, Ford K, Cummins MM, Stockler MR, Solomon BJ, John T, Chih-Hsin Yang J. Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE). JTO Clin Res Rep. 2024 Nov 22;6(2):100771. doi: 10.1016/j.jtocrr.2024.100771.

2023

Agar MR, Nowak AK, Hovey EJ, Barnes EH, Simes J, Vardy JL, Wheeler HR, Kong BY, Leonard R, Hall M, Tim E, Spyridopoulos D, Sim HW, Lwin Z, Dowling A, Harrup R, Jennens R, Kichenadasse G, Dunlop T, Gzell C, Koh ES. Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study. BMJ Support Palliat Care. 2023 Sep;13(3):354-362. doi: 10.1136/spcare-2022-004119. Epub 2023 Feb 17.

Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med. 2023 Mar 2;388(9):804-812. doi: 10.1056/NEJMoa2203086.

Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.

Bui KT, Li Z, Dhillon HM, Kiely BE, Blinman P. Scanxiety Conversations on Twitter: Observational Study. JMIR Cancer. 2023 Apr 19;9:e43609. doi: 10.2196/43609.

Butow P, Faris MM, Shaw J, Kelly P, He S, Harris M, Cuddy J, Masya L, Geerligs L, Kelly B, Girgis A, Rankin N, Beale P, Hack TF, Kirsten L, Dhillon H, Grimison P, Viney R, Clayton JM, Schlub T; ADAPT Program Group; Shepherd HL. Effect of core versus enhanced implementation strategies on adherence to a clinical pathway for managing anxiety and depression in cancer patients in routine care: a cluster randomised controlled trial. Implement Sci. 2023 May 22;18(1):18. doi: 10.1186/s13012-023-01269-0.

Butow P, Havard PE, Butt Z, Juraskova I, Sharpe L, Dhillon H, Beatty L, Beale P, Cigolini M, Kelly B, Chan RJ, Kirsten L, Best MC, Shaw J. Stakeholder perspectives on the impact of COVID-19 on oncology services: a qualitative study. Support Care Cancer. 2023 Jul 24;31(8):491. doi: 10.1007/s00520-023-07916-y.

Campbell I, Wetzig N, Ung O, Espinoza D, Farshid G, Collins J, Kollias J, Gebski V, Mister R, Simes RJ, Stockler MR, Gill G. 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. Breast. 2023 Aug;70:70-75. doi: 10.1016/j.breast.2023.06.009. Epub 2023 Jun 23.

Campbell R, King MT, Stockler MR, Lee YC, Roncolato FT, Friedlander ML. Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice. Patient Relat Outcome Meas. 2023 May 8;14:111-126. doi: 10.2147/PROM.S297301.

Conduit C, Lewin J, Weickhardt A, Lynam J, Wong S, Grimison P, Sengupta S, Pranavan G, Parnis F, Bastick P, Campbell D, Hansen AR, Leonard M, McJannett M, Stockler MR, Gibbs P, Toner G, Davis ID, Tran B, Kuchel A. Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncol Pract. 2023 Nov;19(11):973-980. doi: 10.1200/OP.23.00191. Epub 2023 Jun 16.

Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C, Mallesara G, Guminski A, Lee A, Stockler MR, Hickey A, Eu P, Joshua AM, Crumbaker M, Nguyen A. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023 Mar 1;15:17588359231156392. doi: 10.1177/17588359231156392.

Fardell JE, Irwin CM, Vardy JL, Bell ML. Anxiety, depression, and concentration in cancer survivors: National Health and Nutrition Examination Survey results. Support Care Cancer. 2023 Apr 15;31(5):272. doi: 10.1007/s00520-023-07710-w.

Fardell JE, Tan SYC, Kerin-Ayres K, Dhillon HM, Vardy JL. Symptom Clusters in Survivorship and Their Impact on Ability to Work among Cancer Survivors. Cancers (Basel). 2023 Oct 24;15(21):5119. doi: 10.3390/cancers15215119.

Fardell JE, Walker A, Chan RJ, Vardy JL. Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts? JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad026. doi: 10.1093/jncics/pkad026.

Kasherman L, Yoon WH, Tan SYC, Malalasekera A, Shaw J, Vardy J. Cancer survivorship programs for patients from culturally and linguistically diverse (CALD) backgrounds: a scoping review. J Cancer Surviv. 2023 Aug 12. doi: 10.1007/s11764-023-01442-w. Epub ahead of print.

Lee J, Currow D, Lovell M, Phillips JL, McLachlan A, Ritchie M, Brown L, Fazekas B, Aggarwal R, Seah D, Sheehan C, Chye R, Noble B, McCaffrey N, Aggarwal G, George R, Kow M, Ayoub C, Linton A, Sanderson C, Mittal D, Rao A, Prael G, Urban K, Vandersman P, Agar M. Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study. BMJ Open. 2023 Feb 21;13(2):e066125. doi: 10.1136/bmjopen-2022-066125.

Livingstone A, Howard K, Menzies AM, Long GV, Stockler MR, Morton RL. Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment. Patient. 2023 Sep;16(5):497-513. doi: 10.1007/s40271-023-00635-w. Epub 2023 Jun 23.

Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, Bradshaw N, Lee YC, Diamante K, Fyles AW, Small W Jr, Gaffney DK, Khaw P, Brooks S, Thompson JS, Huh WK, Mathews CA, Buck M, Suder A, Lad TE, Barani IJ, Holschneider CH, Van Dyk S, Quinn M, Rischin D, Monk BJ, Stockler MR. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 May;24(5):468-482. doi: 10.1016/S1470-2045(23)00147-X. Epub 2023 Apr 17.

Morris JN, Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Iddawela M, Mackay G, Jefford M. Current landscape of cancer survivorship research in Australia. Asia Pac J Clin Oncol. 2023 Oct;19(5):e305-e313. doi: 10.1111/ajco.13914. Epub 2023 Jan 19.

Naher SK, Mercieca-Bebber R, Siu D, Grimison P, Stockler MR. Prognostic value of patient reported outcomes in advanced gastro-oesophageal cancer: a systematic review. Intern Med J. 2023 Nov;53(11):1946-1955. doi: 10.1111/imj.16209. Epub 2023 Aug 22.

Nahm SH, Martin AJ, Clayton JM, Grimison P, Moth EB, Pavlakis N, Sjoquist K, Smith-Uffen MES, Tognela A, Vasista A, Stockler MR, Kiely BE. Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad094. doi: 10.1093/jncics/pkad094.

Nahm SH, Stockler MR, Kiely BE. Voluntary assisted dying: estimating life expectancy to determine eligibility. Med J Aust. 2023 Jan 16;218(1):48. doi: 10.5694/mja2.51790. Epub 2022 Nov 24.

Obeid LA, Dhillon HM, Tan SY, Vardy JL. Is there a need for change in cancer survivorship care? A qualitative exploration of survivor experiences and needs at the Sydney Cancer Survivorship Centre Clinic. Support Care Cancer. 2023 Oct 18;31(12):642. doi: 10.1007/s00520-023-08102-w.

Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23.

Raso KL, Suen M, Turner J, Khatri S, Lin Y, Wildbore C, Becerril-Martinez G, Le Page P, Tan SY, Egger S, Vardy J. Prehabilitation Before Gastrointestinal Cancer Surgery: Protocol for an Implementation Study. JMIR Res Protoc. 2023 Mar 27;12:e41101. doi: 10.2196/41101.

Shafiei M, Galettis P, Beale P, Reuter SE, Martin JH, McLachlan AJ, Blinman P. Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study. Cancer Chemother Pharmacol. 2023 Aug;92(2):135-139. doi: 10.1007/s00280-023-04552-5. Epub 2023 Jun 23.

Shafiei M, Mahmood A, Beale P, Galettis P, Martin J, McLachlan AJ, Blinman P. Dried Blood Spot Sampling in the Monitoring of Anticancer Therapy for Solid Tumors: A Systematic Review. Ther Drug Monit. 2023 Jun 1;45(3):293-305. doi: 10.1097/FTD.0000000000001082. Epub 2023 Feb 3.

Sjoquist KM, Martin A, Pavlakis N, Goldstein D, Tsobanis E, Moses D, Maher R, Hague W, Gebski V, Stockler MR, Simes RJ; Australasian Gastro-Intestinal Trials Group (AGITG). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. J Cancer Res Clin Oncol. 2023 Jul;149(8):4959-4965. doi: 10.1007/s00432-022-04404-4. Epub 2022 Oct 31.

Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3.

Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization. Int J Gynecol Cancer. 2023 Apr 3;33(4):628-630. doi: 10.1136/ijgc-2022-004236.

Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization. J Gynecol Oncol. 2023 Mar;34(2):e33. doi: 10.3802/jgo.2023.34.e33.

Teng C, Chiarovano E, Tighe D, Bui KT, Venkatesha, Blinman PL, MacDougall HG, Vardy JL. Exploring assessment of balance using virtual reality in patients at risk of chemotherapy-induced peripheral neuropathy. Intern Med J. 2023 Aug;53(8):1356-1365. doi: 10.1111/imj.15861. Epub 2022 Sep 14.

Yenson VM, Amgarth-Duff I, Brown L, Caperchione CM, Clark K, Cross A, Good P, Landers A, Luckett T, Philip J, Steer C, Vardy JL, Wong AK, Agar MR. Defining research priorities and needs in cancer symptoms for adults diagnosed with cancer: an Australian/New Zealand modified Delphi study. Support Care Cancer. 2023 Jul 3;31(7):436. doi: 10.1007/s00520-023-07889-y.

Yung A, Kay J, Beale P, Gibson KA, Shaw T. Computer-Based Decision Tools for Shared Therapeutic Decision-making in Oncology: Systematic Review. JMIR Cancer. 2021 Oct 26;7(4):e31616. doi: 10.2196/31616.

2022

Bui, K.T., Kiely, B.E., Dhillon, H.M., Brown, C., Xu, K., Shafiei, M. & Blinman, P. Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey. Support Care Cancer 2022; 30(1), 1-9. doi: 10.1007/s00520-021-06454-9.

Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16.

Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, Connell RO, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT; GCIG Symptom Benefit Group. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecol Oncol. 2022 Aug;166(2):254-262. doi: 10.1016/j.ygyno.2022.05.024. Epub 2022 Jun 17.

Conduit C, Mak B, Qu W, Lulio JD, Burder R, Bressel M, Cusick T, Dhillon HM, Lourenço RA, Underhill C, Torres J, Crumbaker M, Honeyball F, Linton A, Allen R, Davis ID, Clark SJ, Horvath LG, Mahon KL. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol). Ther Adv Med Oncol. 2022 Apr 18;14:17588359221092486. doi: 10.1177/17588359221092486. eCollection 2022.

Hayne D, Grummet J, Espinoza D, McCombie SP, Chalasani V, Ford KS, Frydenberg M, Gilling P, Gordon B, Hawks C, Konstantatos A, Martin AJ, Nixon A, O'Brien C, Patel MI, Sengupta S, Shahbaz S, Subramaniam S, Williams S, Woo HH, Stockler MR, Davis ID, Buchan N; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). 'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). BJU Int. 2022 May;129(5):591-600. doi: 10.1111/bju.15552. Epub 2021 Jul 30.

Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142.

Lovell MR, Phillips JL, Luckett T, Lam L, Boyle FM, Davidson PM, Cheah SL, McCaffrey N, Currow DC, Shaw T, Hosie A, Koczwara B, Clarke S, Lee J, Stockler MR, Sheehan C, Spruijt O, Allsopp K, Clinch A, Clark K, Read A, Agar M. Effect of Cancer Pain Guideline Implementation on Pain Outcomes Among Adult Outpatients With Cancer-Related Pain: A Stepped Wedge Cluster Randomized Trial. JAMA Netw Open. 2022 Feb 1;5(2):e220060. doi: 10.1001/jamanetworkopen.2022.0060.

Mak B, Lin HM, Duong T, Mahon KL, Joshua AM, Stockler MR, Gurney H, Parnis F, Zhang A, Scheinberg T, Wittert G, Butler LM, Sullivan D, Hoy AJ, Meikle PJ, Horvath LG. Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. Cancers (Basel). 2022 Sep 30;14(19):4792. doi: 10.3390/cancers14194792.

Mak B, Lin HM, Kwan EM, Fettke H, Tran B, Davis ID, Mahon K, Stockler MR, Briscoe K, Marx G, Zhang A, Crumbaker M, Tan W, Huynh K, Meikle TG, Mellett NA, Hoy AJ, Du P, Yu J, Jia S, Joshua AM, Waugh DJ, Butler LM, Kohli M, Meikle PJ, Azad AA, Horvath LG. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Med. 2022 Mar 25;20(1):112. doi: 10.1186/s12916-022-02298-0.

Moth EB, Stockler MR, Kiely BE. Estimating prognosis in advanced cancer: Time to embrace uncertainty. J Geriatr Oncol. 2022 Apr;13(3):389-390. doi: 10.1016/j.jgo.2021.11.014. Epub 2021 Dec 9.

Nahm SH, Stockler MR, Kiely BE. Voluntary assisted dying: estimating life expectancy to determine eligibility. Med J Aust. 2022 Aug 15;217(4):178-179. doi: 10.5694/mja2.51648. Epub 2022 Jul 24.

Nahm SH, Stockler MR, Martin AJ, Grimison P, Fox P, Zielinski R, Hawson GA, Tattersall MH, Kiely BE. Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals. Support Care Cancer. 2022 Sep;30(9):7763-7772. doi: 10.1007/s00520-022-07167-3. Epub 2022 Jun 15.

Oza B, Eisen T, Frangou E, Stewart GD, Bex A, Ritchie AWS, Kaplan R, Smith B, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Joniau S, Hancock B, Hermann GG, Bellmunt J, Parmar MKB, Royston P, Meade A. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. J Clin Oncol. 2022 Jun 1;40(16):1772-1782. doi: 10.1200/JCO.21.01090. Epub 2022 Feb 25.

Shi H, Rath EM, Lin RCY, Sarun KH, Clarke CJ, McCaughan BC, Ke H, Linton A, Lee K, Klebe S, Maitz J, Song K, Wang Y, Kao S, Cheng YY. 3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies.Front Oncol. 2022 Aug 26;12:973576. doi: 10.3389/fonc.2022.973576. eCollection 2022.

Sjoquist KM, Martin A, Pavlakis N, Goldstein D, Tsobanis E, Moses D, Maher R, Hague W, Gebski V, Stockler MR, Simes RJ; Australasian Gastro-Intestinal Trials Group (AGITG). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. J Cancer Res Clin Oncol. 2022 Oct 31. doi: 10.1007/s00432-022-04404-4. Epub ahead of print.

Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileshkin L, Antill Y; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers (Basel). 2022 Dec 30;15(1):254. doi: 10.3390/cancers15010254.

Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. J Clin Oncol. 2022 Mar 10;40(8):837-846. doi: 10.1200/JCO.21.00941. Epub 2021 Dec 20.

Stockler MR, Martin AJ, Dhillon HM, Davis ID, Sweeney CJ. Reply to L. Marandino et al. J Clin Oncol. 2022 Jul 1;40(19):2176-2177. doi: 10.1200/JCO.22.00497. Epub 2022 Apr 21.

Teng C, Egger S, Blinman PL, Vardy JL. Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial. Support Care Cancer. 2022;31(1):52. Published 2022 Dec 17. doi:10.1007/s00520-022-07463-y.

Teng C, Vardy JL. "POLAR-izing" Findings from trials of neuroprotection for oxaliplatin neuropathy. JNCI Cancer Spectrum. 2022 Dec 6(6): pakc076 doi: 10.1093/jncics/pkac076.

Teng C, Venkatesha, Blinman PL, Vardy JL. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors. J Natl Compr Canc Netw. 2022;20(12):1308-1315. doi:10.6004/jnccn.2022.7050.

Teng, C., Chiarovano, E., Tighe, D., Bui, K.T., Venkatesha, V., Blinman, P.L., MacDougall H.G. & Vardy, J.L. Exploring assessment of balance using virtual reality in patients at risk of chemotherapy-induced peripheral neuropathy. Intern Med J; Advanced online publication 2022. doi: 10.1111/imj.15861.

Zomerdijk N, Panozzo S, Mileshkin L, Yoong J, Nowak AK, Stockler MR, Philip J. Palliative care facilitates the preparedness of caregivers for thoracic cancer patients. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13716. doi: 10.1111/ecc.13716. Epub 2022 Sep 28.

Medical Oncology Research

Selected Grants

Our Publications

2024

Medical Oncology Research

Medical Oncology Research

Our Organisation

Make a Donation

Our Hospitals

Care in our Community

Right to Information

Your feedback

Plans

Publications

Quick Links